A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Last updated: May 30, 2025
Sponsor: Eisai Inc.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Neoplasms

Liver Cancer

Endometrial Cancer

Treatment

Lenvatinib

Paclitaxel

Doxorubicin

Clinical Study ID

NCT04008797
E7386-J081-102
2023-510275-64-00
2022-003300-32
2023-505588-34-00
2023-510275-64
  • Ages > 18
  • All Genders

Study Summary

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. HCC part only: Participants with confirmed diagnosis of unresectable HCC with any of the followingcriteria:

  2. Histologically or cytologically confirmed diagnosis of HCC, excludingfibrolamellar, sarcomatoid or mixed cholangio-HCC tumors

  3. Clinically confirmed diagnosis of HCC according to American Association for theStudy of Liver Diseases (AASLD) criteria, including cirrhosis of any etiologyand/or chronic hepatitis B or C infection ST part only (except for HCC): Participants with histologically or cytologically confirmed diagnosis of solid tumorfor which no alternative standard therapy or no effective therapy exists

  4. Life expectancy of >=12 weeks

  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

  6. All AEs due to previous anti-cancer therapy have either returned to Grade 0 to 1except for alopecia or up to Grade 2 peripheral neuropathy (renal/bone marrow/liverfunction should meet the inclusion criteria)

  7. Adequate washout period before study drug administration:

  8. Chemotherapy and radiotherapy: 3 weeks or 5 times the half-life, whichever isshorter

  9. Any antitumor therapy with antibody: 4 weeks or more

  10. Any investigational drug or device: 4 weeks or more

  11. Blood/platelet transfusion or granulocyte colony-stimulating factor (G-CSF): 2weeks or more Note: Participants must have recovered from all radiation-relatedtoxicities, not require corticosteroids, and not had radiation pneumonitis

  12. Adequate controlled blood pressure (BP), renal function, bone marrow function, liverfunction, and serum mineral level

  13. At least one measurable lesion based on mRECIST (for HCC Subparts in Dose EscalationPart) or on RECIST 1.1 (for Other ST Subparts in Dose Escalation Part and allsubparts in Expansion and Dose Optimization Parts) meeting following criteria

  • At least 1 lesion of >=1.0 centimeter (cm) in the longest diameter for anon-lymph node or >=1.5 cm in the short-axis diameter for a lymph node that isserially measurable according to RECIST 1.1 using computerized tomography (CT)/magnetic resonance imaging (MRI)

  • Lesions that have had external beam radiotherapy or loco-regional therapiessuch as radiofrequency ablation, or transarterial chemoembolisation (TACE)/transarterial embolization (TAE) must show evidence of progressive diseasebased on RECIST 1.1 to be deemed a target lesion

  1. For HCC participants only: Child-Pugh score A. Note: If Child-Pugh score 7 or morewas observed during Screening or Baseline, the participant is ineligible andre-assessment of the Child-Pugh score is not permitted

  2. For HCC participants only: Participants categorized to stage B (not amenable tolocoregional therapy or refractory to locoregional therapy, and not amenable to acurative treatment), or stage C based on Barcelona Clinic Liver Cancer (BCLC)staging system

  3. For HCC Subpart in Expansion Part only: prior systemic therapy for locally advancedor metastatic disease is as defined below a. Participants who have received only one prior line of immuno oncology (IO) basedregimen and have progressed on or after prior treatment with IO based regimen, or IOineligible participants who have received no prior systemic therapy. Participantswho previously received lenvatinib treatment are ineligible

  4. For CRC Subpart in Expansion Part only: participants must have received at least 2prior regimens (not exceeding 4 prior regimens) or could not tolerate standardtreatment and must have received the following prior therapies in the metastaticsetting if approved and locally available (progressed on at least 1 prior regimen inthe metastatic setting or could not tolerate standard treatment): Note: Adjuvant chemotherapy counts as prior systemic treatment if there isdocumented disease progression within 6 months of treatment completion Note: If aparticipant is determined to be intolerant to prior standard treatment, theparticipant must have received at least of 2 cycles of that therapy Note:Participants who have received oral tyrosine kinase inhibitor (example, regorafenib)are ineligible

  5. Fluoropyrimidine, irinotecan and oxaliplatin with or without an anti-Vascularendothelial growth factor (VEGF) monoclonal antibody (mAb) (example,bevacizumab) Note: Capecitabine is acceptable as equivalent to fluoropyrimidinein prior treatment Note: Participants who have previously receivedfluoropyrimidine, oxaliplatin, and irinotecan as part of the same and onlychemotherapy regimen, example, FOLFOXIRI or FOLFIRINOX, may be eligible afterdiscussion with the Sponsor

  6. Chemotherapy with anti- epidermal growth factor receptor (EGFR) mAb (cetuximabor panitumumab) for participants with rat sarcoma virus (RAS) (Kirsten ratsarcoma viral oncogene homolog [KRAS)/ NRAS]) wild type (WT) CRC Note: RAS (KRAS/NRAS) WT participants with right or left CRC lesions who may have notbeen treated with anti-EGFR mAb based on local guidelines are eligible

  7. BRAF inhibitor (in combination with cetuximab ± binimetinib) for BRAF V600Emutated tumors

  8. Immune checkpoint inhibitor for participants with microsatelliteinstability-high (MSI-H) CRC

  9. For EC Subpart in Expansion Part only: Participants must have EC that has progressedafter prior platinum-based chemotherapy and an anti-programmed cell death (ligand) 1 (PD-[L])1)-directed therapy for EC (participants ineligible for IO therapy who haveprogressed after prior platinum-based chemotherapy are eligible). Up to 3 priorsystemic therapies, of which up to 2 for metastatic or locally advanced disease, arepermitted Note: There is no restriction regarding prior hormonal therapies For DoseOptimization Part only: Participants must have EC that has progressed after priorplatinum-based chemotherapy and an anti-PD-(L)1-directed therapy for EC. Up to 3lines of prior therapy, regardless of setting, are allowed. Note: Prior hormonaltherapy and radiation are allowed and do not count as prior lines of therapy.

Exclusion

Exclusion Criteria:

  1. Any of cardiac conditions as follows:
  • Heart failure New York Heart Association (NYHA) Class II or above

  • Prolongation of QT interval with Fridericias correction (QTcF) to greater than (>) 480 millisecond (msec)

  • Left ventricular ejection fraction (LVEF) less than (<) 50 percent (%)

  1. Major surgery within 21 days or minor surgery (that is, simple excision) within 7days prior to starting study drug. Participant must have recovered from the surgeryrelated toxicities to less than Grade 2 Note: Adequate wound healing after majorsurgery must be assessed clinically, independent of time elapsed for eligibility

  2. Known to be human immunodeficiency virus (HIV) positive Note: the sponsor hasevaluated whether to include participant with HIV. Given that this is the firstcombination study of E7386 with lenvatinib and that the main mechanism of action ofE7386 is immunomodulation of the tumor microenvironment along with the fact thatseveral anti-retroviral therapies have drug-drug interaction with cytochrome P450 3A (CYP3A) substrates, the sponsor has decided not to include these participants at thecurrent time. However, further considerations will be made moving forward based onnew emerging data Note: HIV testing is required at screening only when mandated bylocal health authority

  3. Participants with proteinuria on urine dipstick testing will undergo 24-hour urinecollection for quantitative assessment of proteinuria. Participants with urineprotein >=1 gram per 24 hour will be ineligible

  4. Active infection requiring systemic treatment (Except for Hepatitis B and/or C [HBV/HCV] infection in HCC participants) In case of HBsAg (+) participants in HCC participants:

  • Antiviral therapy for HBV is not ongoing

  • HBV viral load is 2000 international unit per milliliter (IU/mL) or more at theScreening Period although antiviral therapy for HBV is ongoing

  • Has dual active HBV infection (HBsAg (+) and/or detectable HBV deoxyribonucleicacid [DNA]) and HCV infection (anti-HCV Ab (+) and detectable HCV ribonucleicacid [RNA]) at study entry

  1. Diagnosed with meningeal carcinomatosis

  2. Participants with central nervous system metastases are only eligible if they havebeen previously treated and are radiologically stable, (that is, without evidence ofprogression for at least 4 weeks prior to first dose of study treatment by repeatimaging), clinically stable, and without requirement of steroid treatment for atleast 14 days prior to first dose of study treatment

  3. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiringactive treatment, including the use of oxygen

  4. Any of bone disease/conditions as follows:

  • T-score of < minus (-) 3.0 at the left or right total hip, left or rightfemoral neck or lumbar spine (L1-L4) as determined by dual energy x-rayabsorptiometry (DXA) scan. Participants with T-score <-2.5 to -3.0 can only beincluded if treatment with a bisphosphonate (example, zoledronic acid) ordenosumab has been started at least 14 days and no more than 6 months prior tothe first dose of study drug

  • Metabolic bone disease, such as hyperparathyroidism, Paget's disease orosteomalacia

  • Symptomatic hypercalcemia requiring bisphosphonate therapy

  • History of any fracture within 6 months prior to starting study drug

  • Bone metastasis requiring orthopedic intervention

  • Bone metastasis not being treated by bisphosphonate or denosumab. Participantsmay be included if treatment with bisphosphonate or denosumab has been startedat least 14 days prior to the first dose of study drug. Participants withprevious solitary bone lesions controlled with radiotherapy are eligible

  • History of symptomatic vertebral fragility fracture or any fragility fractureof the hip, pelvis, wrist or other location (defined as any fracture without ahistory of trauma or because of a fall from standing height or less)

  • Moderate (25% to 40% decrease in the height of any vertebrae) or severe (>40%decrease in the height of any vertebrae) morphometric vertebral fracture atbaseline

  1. History of malignancy (except for original disease, or definitively treated melanomain-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ [example,bladder or cervix]) within the past 24 months prior to the first dose of study drug

  2. For HCC Subpart in Dose Escalation Part only: Participants who experienceddiscontinuation of lenvatinib, 2 or more dose reductions of lenvatinib required frominitial dose level of this study due to its toxicity, or participants whoexperienced single dose reduction or consecutive >=8 days dose interruption oflenvatinib within 60 days from the first dose, due to its toxicity. HCC Subpart inExpansion Part only: Participants who previously received lenvatinib treatment areineligible. EC Subpart in Expansion Part only: Participants previously treated with lenvatinibwho experienced discontinuation of lenvatinib due to toxicity, or dose reduction toless than 10 mg of lenvatinib due to toxicity within 60 days from the first dose. EC Dose Optimization Part only: Participants who previously received lenvatinibtreatment are ineligible.

  3. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeuticInternational Normalized Ratio (INR) monitoring for HCC participants only (example,warfarin or similar agents). Treatment with low molecular weight heparin and factorX inhibitors is permitted. Treatment with antiplatelet agents is prohibited for HCCparticipants in Dose Escalation Part only

  4. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug

  5. For HCC participants only: History of hepatic encephalopathy within 6 months priorto starting study drug

  6. For EC Subpart in Expansion and Dose Optimization Parts only: carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma, and endometrialstromal sarcomas

  7. Has preexisting >=Grade 3 gastrointestinal or non-gastrointestinal fistula

  8. Evidence of current Coronavirus disease 2019 (COVID-19) infection or ongoingunrecovered active sequelae of COVID-19 infection

  9. Males who have not had a successful vasectomy (confirmed azoospermia) if theirfemale partners meet the exclusion criteria above (that is, the female partners areof childbearing potential and are not willing to use a highly effectivecontraceptive method throughout the study period and after study drugdiscontinuation). No sperm donation is allowed during the study period and afterstudy drug discontinuation

  10. Has a known psychiatric or substance abuse disorder that would interfere with theparticipant ability to cooperate with the requirements of the study

  11. Evidence of clinically significant disease (example, cardiac, respiratory,gastrointestinal, renal disease) that in the opinion of the investigator couldaffect the participant safety or interfere with the study assessments

  12. Scheduled for major surgery during the study

Study Design

Total Participants: 301
Treatment Group(s): 4
Primary Treatment: Lenvatinib
Phase: 1/2
Study Start date:
July 11, 2019
Estimated Completion Date:
August 31, 2027

Connect with a study center

  • Sunnybrook Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • CHUM, Unit for Innovative Therapies

    Montreal, Quebec
    Canada

    Site Not Available

  • McGill University Health Centre

    Montreal, Quebec
    Canada

    Site Not Available

  • Beijing Cancer Hospital

    Beijing,
    China

    Site Not Available

  • Peking Union Medical College Hospital

    Beijing,
    China

    Site Not Available

  • Bethune Hospital of Jilin University

    Changchun,
    China

    Active - Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou,
    China

    Active - Recruiting

  • Sun Yan-sen University Cancer Center

    Guangzhou,
    China

    Site Not Available

  • Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University

    Guangzhou,
    China

    Site Not Available

  • Cancer Hospital of Shandong First Medical University

    Jinan,
    China

    Site Not Available

  • Yunnan Cancer Hospital

    Kunming,
    China

    Active - Recruiting

  • Fudan University Cancer Center

    Shanghai,
    China

    Active - Recruiting

  • The Tenth People's Hospital; Shanghai Tongji University

    Shanghai,
    China

    Active - Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen,
    China

    Site Not Available

  • Tianjin Cancer Hospital

    Tianjin,
    China

    Site Not Available

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou,
    China

    Site Not Available

  • Rigshospatalet

    Copenhagen,
    Denmark

    Site Not Available

  • Odense University Hospital

    Odense,
    Denmark

    Site Not Available

  • CHU Amiens-Picardie (Hopital Sud)

    Amiens, 80000
    France

    Completed

  • CHU Bordeaux

    Bordeaux, 33075
    France

    Site Not Available

  • CHU Cavale Blanche

    Brest, 29200
    France

    Active - Recruiting

  • Centre François Baclesse

    Caen, 14000 Caen
    France

    Site Not Available

  • Centre Jean Perrin

    Clermont-Ferrand, 63000 Clermont-Ferrand
    France

    Site Not Available

  • Hôpital Beaujon

    Clichy, 92110
    France

    Site Not Available

  • Centre Georges-François Leclerc

    Dijon, 21000
    France

    Site Not Available

  • Grenoble University Hospital (Centre Hospitalier Universitaire Grenoble Alpes)

    La Tronche, 38700
    France

    Site Not Available

  • CHU de LILLE - Hôpital HURIEZ

    Lille, 59037
    France

    Site Not Available

  • Centre Léon Bérard

    Lyon, 69008 Lyon
    France

    Site Not Available

  • Hepatology, Hopital de la Croix-Rousse - 103 grande rue de la Croix-Rousse

    Lyon, 69004
    France

    Site Not Available

  • Institut Paoli-Calmettes

    Marseille, 3009 Marseille
    France

    Site Not Available

  • Centre Antoine Lacassagne

    Nice, 06100 Nice
    France

    Site Not Available

  • AP-HP Université de Paris, Port Royal

    Paris, 75014 Paris
    France

    Site Not Available

  • APHP Hospital Saint-Antoine

    Paris, 75012
    France

    Site Not Available

  • Hopital Europeen Georges-Pompidou (HEGP)

    Paris, 75015
    France

    Site Not Available

  • Hopital de la Croix Saint-Simon

    Paris, 75020
    France

    Site Not Available

  • Institut Curie - Centre de Recherche

    Paris, 75005
    France

    Active - Recruiting

  • Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)(Hopitaux de Bordeaux) - Groupe hospitalier Sud - Hopital Haut-Levequ

    Pessac, 33604
    France

    Site Not Available

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, 86000 Poitiers
    France

    Active - Recruiting

  • Insitute de Cancérologie de l'Ouest - Centre René Gauducheau

    Saint-Herblain, Saint-Herblain 44800
    France

    Site Not Available

  • ICANs

    Strasbourg, 67200 Strasbourg
    France

    Site Not Available

  • Gustave Roussy Institute (IGR)

    Villejuif, 94805
    France

    Active - Recruiting

  • Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche

    Ancona,
    Italy

    Site Not Available

  • Istituto Clinico Humanitas, Rozzano

    Milan,
    Italy

    Site Not Available

  • Fondazione Policlinico Gemelli IRCCS

    Rome,
    Italy

    Site Not Available

  • Eisai Trial Site #5

    Nagoya, Aichi
    Japan

    Active - Recruiting

  • Eisai Trial Site #11

    Toyoake, Aichi
    Japan

    Site Not Available

  • Eisai Trial Site #2

    Kashiwa, Chiba
    Japan

    Site Not Available

  • Eisai Trial Site #8

    Matsuyama, Ehime
    Japan

    Completed

  • Eisai Trial Site #7

    Kurume, Fukuoka
    Japan

    Site Not Available

  • Eisai site #13

    Akashi, Hyogo
    Japan

    Site Not Available

  • Eisai Trial Site #10

    Kawasaki, Kanagawa
    Japan

    Site Not Available

  • Eisai Trial Site #12

    Kamigyo-ku, Kyoto
    Japan

    Completed

  • Eisai Trial Site #3

    Osakasayama, Osaka
    Japan

    Site Not Available

  • Eisai Trial Site #9

    Hidaka, Saitama
    Japan

    Active - Recruiting

  • Eisai Trial Site #1

    Chuo-Ku, Tokyo
    Japan

    Site Not Available

  • Eisai Trial Site #6

    Koto-ku, Tokyo
    Japan

    Site Not Available

  • Eisai Site 15

    Minato-ku, Tokyo
    Japan

    Site Not Available

  • Eisai Trial Site #4

    Chiba,
    Japan

    Site Not Available

  • Eisai site #14

    Niigata,
    Japan

    Site Not Available

  • Eisai Trial Site #1

    Seongnamsi Bundang, Gyeonggi-Do
    Korea, Republic of

    Site Not Available

  • Eisai Trial Site #2001

    Seongnamsi Bundang, Gyeonggi-Do
    Korea, Republic of

    Active - Recruiting

  • National Cancer Center

    Goyang-si Gyeonggi-do, Ilsandong-gu
    Korea, Republic of

    Site Not Available

  • Korea University Guro Hospital

    Guro-gu, Seoul
    Korea, Republic of

    Active - Recruiting

  • Eisai Trial Site #2005

    Jongno-gu, Seoul
    Korea, Republic of

    Active - Recruiting

  • Eisai Trial Site #5

    Jongno-gu, Seoul
    Korea, Republic of

    Completed

  • Seoul National University Hospital

    Jongno-gu, Seoul
    Korea, Republic of

    Site Not Available

  • Seoul St. Mary's Hospital

    Seocho-Gu, Seoul
    Korea, Republic of

    Site Not Available

  • Eisai Trial Site #2

    Seodaemun, Seoul
    Korea, Republic of

    Site Not Available

  • Eisai Trial Site #2002

    Seodaemun, Seoul
    Korea, Republic of

    Active - Recruiting

  • Asan Medical Centre

    Songpa-Gu, Seoul
    Korea, Republic of

    Site Not Available

  • Eisai Trial Site #2004

    Songpa-gu, Seoul
    Korea, Republic of

    Active - Recruiting

  • Eisai Trial Site #4

    Songpa-gu, Seoul
    Korea, Republic of

    Site Not Available

  • Eisai Trial Site #2003

    Seoul,
    Korea, Republic of

    Active - Recruiting

  • Eisai Trial Site #3

    Seoul,
    Korea, Republic of

    Site Not Available

  • H. Clinico San Carlos

    San Carlos, Madrid
    Spain

    Site Not Available

  • Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO)

    Barcelona,
    Spain

    Site Not Available

  • University Hospital A Coruña

    Coruna,
    Spain

    Site Not Available

  • Hospital Universitario de Jaén

    Jaen,
    Spain

    Site Not Available

  • Clínica Universidad de Navarra

    Madrid,
    Spain

    Site Not Available

  • Hospital Universitario 12 de Octubre

    Madrid,
    Spain

    Site Not Available

  • Chang Gung Medical Foundation - Kaohsiung Branch

    Kao-Hsiung,
    Taiwan

    Site Not Available

  • Taichung Veterans General Hospital

    Taichung,
    Taiwan

    Active - Recruiting

  • National Cheng Kung University Hospital

    Tainan,
    Taiwan

    Completed

  • National Taiwan University Hospital

    Taipei,
    Taiwan

    Site Not Available

  • Taipei Veterans General Hospital

    Taipei,
    Taiwan

    Completed

  • Chang Gung Medical Foundation - Linkou Branch

    Taoyuan,
    Taiwan

    Site Not Available

  • UAMS

    Little Rock, Arkansas 72205
    United States

    Site Not Available

  • University of California San Diego (UCSD) - Moores Cancer Center(All)

    La Jolla, California 92037
    United States

    Active - Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Completed

  • Pasadena Liver Center

    Pasadena, California 91105
    United States

    Site Not Available

  • California Pacific Medical Center

    San Francisco, California 94066
    United States

    Site Not Available

  • UCLA University of California - Los Angeles

    Santa Monica, California 90404
    United States

    Site Not Available

  • John Muir Clinical Research

    Walnut Creek, California 94598
    United States

    Site Not Available

  • University of Colorado Cancer Center - Anschutz Medical Campus

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Uni. Of Miami- Sylvester Cancer Centre

    Miami, Florida 33136
    United States

    Site Not Available

  • Florida Cancer Specialists - South

    Sarasota, Florida 34236
    United States

    Site Not Available

  • Florida Cancer Specialists - East

    West Palm Beach, Florida 33401
    United States

    Site Not Available

  • Women's Cancer Care - Covington, LA

    Covington, Louisiana 70433
    United States

    Site Not Available

  • University Of Mississippi Medical Center

    Jackson, Mississippi 39216
    United States

    Site Not Available

  • Kansas City Research Institute

    Kansas City, Missouri 64131
    United States

    Completed

  • Montefiore Medical Center (MMC) - Jack D. Weiler Hospital

    Bronx, New York 10461
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Site Not Available

  • Perlmutter Cancer Center- NYU Langone Health

    New York, New York 10016
    United States

    Active - Recruiting

  • MetroHealth Medical Center

    Cleveland, Ohio 44109
    United States

    Site Not Available

  • ProMedica Flower Hospital

    Sylvania, Ohio 43560
    United States

    Site Not Available

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma 73104
    United States

    Site Not Available

  • UPMC

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Active - Recruiting

  • Sanford Cancer Centre

    Sioux Falls, South Dakota 57106
    United States

    Site Not Available

  • Tennessee Oncology

    Nashville, Tennessee 37211
    United States

    Site Not Available

  • Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville

    Nashville, Tennessee 37232
    United States

    Site Not Available

  • Mary Crowley Cancer Research

    Dallas, Texas 75230
    United States

    Site Not Available

  • University of Texas Southwestern Medical

    Dallas, Texas 75390
    United States

    Site Not Available

  • MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

  • Fred Hutchinson/University of Washington Cancer Consortium

    Seattle, Washington 98109
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.